Медицинская литература. Новинки

 

 

 

 

 

 

Ведение больных с дифференцированными нейроэндокринными опухолями илеоеюнальной локализации (по материалам международных клинических рекомендаци)

Вы можете загрузить полный текст статьи в формате pdf

Ключевые слова:

Литература:
1. Modlin I.M, Lye K. D., Kidd M. A five''decade analysis of
13,715 carcinoid tumors. Cancer 2003; 97: 934–959.
2. Kulke M.H., Mayer R.J. Carcinoid tumors. N. Engl. J. Med.
1999; 340: 858–868.
3. Burke A.P., Thomas R.M., Elsayed A.M., Sobin L.H.
Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer 1997;
79: 1086–1093.
4. Peck J.J., Shields A.B., Boyden A.M. et al. Carcinoid tumors
of the ileum. Am. J. Surg. 1983; 146: 124–132.
5. Modlin I.M., Sandor A. An analysis of 8,305 cases of carcinoid
tumors. Cancer 1997; 79: 813–829.
6. Loftus J.P., van Heerden J.A. Surgical management of gastrointestinal carcinoid tumors. Adv. Surg .1995; 28: 317–336.
7. Godwin J.D. 2nd: Carcinoid tumors. An analysis of 2,837
cases. Cancer 1975; 36: 560– 569.
8. Solcia E.K.G., Sobin L.H. in collaboration with 9 pathologists
from 4 countries: Histological Typing of Endocrine Tumors, ed 2. WHO International Histological Classification of Tumors.
Berlin: Springer, 2000.
9. Berge T., Linell F. Carcinoid tumours. Frequency in a defined
population during a 12'' year period. Acta Pathol. Microbiol.
Scand. [A] 1976; 84: 322–330.
10. Strodel W.E., Talpos G., Eckhauser F., Thompson N. Surgical
therapy for small''bowel carcinoid tumors. Arch. Surg. 1983;
118: 391–397.
11. Marshall J.B., Bodnarchuk G. Carcinoid tumors of the gut.
Our experience over three decades and review of the literature. J. Clin. Gastroenterol. 1993; 16: 123–129.
12. McDermott E.W., Guduric B., Brennan M.F. Prognostic variables in patients with gastrointestinal carcinoid tumours.
Br. J. Surg. 1994; 81: 1007–1009.
13. Arnold R., Rinke A., Klose K.J. et al. Octreotide versus
octreotide plus interferon'' in endocrine gastroenteropancreatic tumors: a randomized trial. Clin. Gastroenterol. Hepatol.
2005; 3: 761–771.
14. Oberg K. Chemotherapy and biotherapy in neuroendocrine
tumors. Curr. Opin. Oncol. 1993; 5: 110–120.
15. Moertel C.G. Karnofsky memorial lecture. An odyssey in the
land of small tumors. J. Clin. Oncol. 1987; 5: 1502–1522.
16. Creutzfeldt W. Carcinoid tumors: development of our knowledge. World J. Surg. 1996; 20: 126–131.
17. Oberg K. The use of chemotherapy in the management of
neuroendocrine tumors. Endocrinol. Metab. Clin. N. Am.
1993; 22: 941–952.
18. Ahlman H., Westberg G., Wangberg B. et al. Treatment of
liver metastases of carcinoid tumors. World. J. Surg. 1996;
20: 196–202.
19. Zuetenhorst J.M., Bonfrer J.M., Korse C.M. et al. Carcinoid
heart disease: the role of urinary 5''hydroxyindoleacetic acid
excretion and plasma levels of atrial natriuretic peptide,
transforming growth factor'' and fibroblast growth factor.
Cancer 2003; 97: 1609–1615.
20. Norheim I., Oberg K., TheodorssonNorheim E. et al.
Malignant carcinoid tumors. An analysis of 103 patients with
regard to tumor localization, hormone production, and survival. Ann. Surg. 1987; 206: 115–125.
21. Makridis C., Rastad J., Oberg K., Akerstrom G. Progression
of metastases and symptom improvement from laparotomy in
midgut carcinoid tumors. World J. Surg. 1996; 20: 900– 907.
22. Westberg G., Wangberg B., Ahlman H. et al. Prediction of
prognosis by echocardiography in patients with midgut carcinoid syndrome. Br. J. Surg. 2001; 88: 865–872.
23. Krenning E.P., Kwekkeboom D.J., Bakker W.H. et al.
Somatostatin receptor scintigraphy with [ 111 In''DTPA'' D Phe 1 ]'' and [ 123 I''Tyr 3 ]'' octreotide: the Rotterdam experience with more than 1,000 patients. Eur. J. Nucl. Med. 1993;
20: 716–731.
24. Hofmann M., Maecke H., Borner R. et al. Biokinetics and
imaging with the somatostatin receptor PET radioligand 68
Ga''DOTATOC: preliminary data. Eur. J. Nucl. Med. 2001; 28:
1751–1757.
25. Ricke J., Klose K.J., Mignon M. et al. Standardisation of
imaging in neuroendocrine tumours: results of a European
delphi process. Eur. J. Radiol. 2001; 37: 8–17.
26. Kaltsas G., Rockall A., Papadogias D. et al. Recent advances
in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur. J. Endocrinol. 2004; 151: 15–27.
27. Bader T.R., Semelka R.C., Chiu V.C. et al. MRI of carcinoid
tumors: spectrum of appearances in the gastrointestinal tract
and liver. J. Magn. Reson. Imaging 2001; 14: 261–269.
28. Orlefors H., Sundin A., Garske U. et al. Wholebody 11
C''5''hydroxytryptophan positron emission tomography as a
universal imaging technique for neuroendocrine tumors:
comparison with somatostatin receptor scintigraphy and
computed tomography. J. Clin. Endocrinol. Metab. 2005; 90:
3392–3400.
29. Koopmans K.P., de Vries E.G., Kema I.P. et al. Staging of carcinoid tumours with 18 F''DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 2006; 7: 728–734.
30. Van Tuyl S.A., van Noorden J.T., Timmer R. et al. Detection of
small''bowel neuroendocrine tumors by video capsule
endoscopy. Gastrointest. Endosc. 2006; 64: 66–72.
31. Swain P. Wireless capsule endoscopy. Gut 2003; 52 (suppl.
4):48–50.
32. Oberg K., Stridsberg M. Chromogranins as diagnostic and
prognostic markers in neuroendocrine tumours. Adv. Exp.
Med. Biol. 2000; 482: 329–337.
33. Ardill J.E., Erikkson B. The importance of the measurement of
circulating markers in patients with neuroendocrine tumours
of the pancreas and gut. Endocr. Relat. Cancer 2003; 10:
459–462.
34. Feldman J.M., O’Dorisio T.M. Role of neuropeptides and
serotonin in the diagnosis of carcinoid tumors. Am. J. Med.
1986; 81: 41–48.
35. Eriksson B., Oberg K. Peptide hormones as tumor markers in
neuroendocrine gastrointestinal tumors. Acta Oncol. 1991;
30: 477– 483.
36. Hamilton S.R. AL: Tumors of the digestive system. Pathology
and Genetics. WHO Classification of Tumours. Lyon: ARC
Press, 2000.
37. Rindi G., Kloppel G., Alhman H. et al. TNM staging of foregut
(neuro)endocrine tumors: a consensus proposal including a
grading system. Virchows Arch. 2006; 449: 395–401.
38. Hemminki K., Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden.
Cancer 2001; 92: 2204–2210.
39. Hemminki K., Li X. Familial carcinoid tumors and subsequent
cancers: a nationwide epidemiologic study from Sweden. Int.
J. Cancer 2001; 94: 444–448.
40. Akerstrom G., Makridis C., Johansson H. Abdominal surgery
in patients with midgut carcinoid tumors. Acta Oncol.1991;
30: 547–553.
41. Rothmund M., Kisker O. Surgical treatment of carcinoid
tumors of the small bowel, appendix, colon and rectum.
Digestion 1994; 55 (suppl. 3): 86–91.
42. Ahlman H., Wangberg B., Jansson S. et al. Interventional
treatment of gastrointestinal neuroendocrine tumours.
Digestion 2000; 62(suppl 1):59–68.
43. Makridis C., Oberg K., Juhlin C. et al. Surgical treatment of
mid''gut carcinoid tumors. World J. Surg. 1990; 14: 377–384.
44. Norton J.A. Surgical management of carcinoid tumors: role of
debulking and surgery for patients with advanced disease.
Digestion 1994; 55(suppl 3):98–103.
45. Goede A.C., Winslet M.C. Surgery for carcinoid tumours of
the lower gastrointestinal tract. Colorectal. Dis. 2003; 5:
123–128.
46. Frilling A., Rogiers X., Malago M. et al. Treatment of liver
metastases in patients with neuroendocrine tumors.
Langenbecks Arch. Surg. 1998; 383: 62–70.
47. Lehnert T., Knaebel H.P. Diagnosis and therapy of liver
metastases of neuroendocrine tumors in German). Hirurg
1997; 68: 122–131.
48. Chen H., Hardacre J.M., Uzar A. et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong
survival? J. Am. Coll. Surg. 1998; 187: 88– 93.
49. Que F.G., Nagorney D.M., Batts K.P. et al. Hepatic resection
for metastatic neuroendocrine carcinomas. Am. J. Surg.
1995; 169: 36–43.
50. Sarmiento J.M., Heywood G., Rubin J. et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for
resection to increase survival. J. Am. Coll. Surg. 2003; 197:
29–37.
51. Chamberlain R.S., Canes D., Brown K.T. et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?
J. Am. Coll. Surg. 2000; 190: 432–445.
52. Norton J.A., Warren R.S., Kelly M.G. et al. Aggressive surgery
for metastatic liver neuroendocrine tumors. Surgery 2003;
134: 1057–1065.
53. Soreide O., Berstad T., Bakka A. et al. Surgical treatment as
a principle in patients with advanced abdominal carcinoid
tumors. Surgery 1992; 111: 48–54.
54. Moertel C.G., Sauer W.G., Dockerty M.B., Baggenstoss A.H.
Life history of the carcinoid tumor of the small intestine.
Cancer 1961; 14: 901–912.
55. Dousset B., SaintMarc O., Pitre J. et al. Metastatic
endocrine tumors: medical treatment, surgical resection, or
liver transplantation. World J. Surg. 1996; 20: 908–915.
56. Chung M.H., Pisegna .J, Spirt M. et al. Hepatic cytoreduction
followed by a novel long''acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the
liver. Surgery 2001; 130: 954–962.
57. Wangberg B., Westberg G., Tylen U. et al. Survival of patients
with disseminated midgut carcinoid tumors after aggressive
tumor reduction.World J. Surg. 1996; 20: 892–899.
58. McEntee G.P., Nagorney D.M., Kvols L.K. et al. Moertel CG,
Grant CS: Cytoreductive hepatic surgery for neuroendocrine
tumors. Surgery 1990; 108: 1091–1096.
59. Eriksson B., Oberg K. Summing up 15 years of somatostatin
analog therapy in neuroendocrine tumors: future outlook.
Ann. Oncol. 1999; 10 (suppl. 2):S31–S38.
60. Eriksson B., Renstrup J., Imam H., Oberg K. High''dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological
effects. Ann. Oncol. 1997; 8: 1041–1044.
61. Wymenga A.N., Eriksson B., Salmela P.I. et al. Efficacy and
safety of prolonged''release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related
symptoms. J. Clin. Oncol. 1999; 17: 1111.
62. Ducreux M., Ruszniewski P., Chayvialle J.A. et аl. The antitumoral effect of the long''acting somatostatin analog lanreotide in neuroendocrine tumors. Am. J. Gastroenterol.
2000; 95: 3276–3281.
63. Di Bartolomeo M., Bajetta E., Buzzoni R. et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical
Oncology Group. Cancer 1996; 77: 402–408.
64. Arnold R., Trautmann M.E., Creutzfeldt W. et al. Somatostatin
analogue octreotide and inhibition of tumour growth in
metastatic endocrine gastroenteropancreatic tumours. Gut
1996; 38: 430–438.
65. Aparicio T., Ducreux M., Baudin E. et al. Antitumour activity of
somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur. J. Cancer 2001; 37: 1014–1019.
66. O’Toole D., Ducreux M., Bommelaer G. et al. Treatment of
carcinoid syndrome: a prospective crossover evaluation of
lanreotide versus octreotide in terms of efficacy, patient
acceptability, and tolerance. Cancer 2000; 88: 770–776.
67. Ruszniewski P., Ducreux M., Chayvialle J.A. et al. Treatment
of the carcinoid syndrome with the longacting somatostatin
analogue lanreotide: a prospective study in 39 patients. Gut
1996; 39: 279–283.
68. Tomassetti P., Migliori M., Gullo L. Slow''release lanreotide
treatment in endocrine gastrointestinal tumors. Am. J.
Gastroenterol. 1998; 93: 1468–1471.
69. Tomassetti P., Migliori M., Corinaldesi R., Gullo L. Treatment
of gastroenteropancreatic neuroendocrine tumours with
octreotide LAR. Aliment Pharmacol. Ther. 2000; 14:
557–560.
70. Faiss S., Pape U.F., Bohmig M. et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of
metastatic neuroendocrine gastroenteropancreatic tumors –
The International Lanreotide and Interferon Alfa Study Group.
J. Clin. Oncol. 2003; 21: 2689–2696.
71. Rubin J., Ajani J., Schirmer W. et al. Octreotide acetate long-acting formulation versus open''label subcutaneous
octreotide acetate in malignant carcinoid syndrome. J. Clin.
Oncol. 1999; 17: 600–606.
72. Ricci S., Antonuzzo A., Galli L. et al. Octreotide аcetate long-acting release in patients with metastatic neuroendocrine
tumors pretreated with lanreotide. Ann. Oncol. 2000; 11:
1127–1130.
73. Leong W.L., Pasieka J.L. Regression of metastatic carcinoid
tumors with octreotide therapy: two case reports and a review
of the literature. J. Surg. Oncol. 2002; 79: 180–187.
74. Saltz L., Trochanowski B., Buckley M. et al. Octreotide as an
antineoplastic agent in the treatment of functional and non-functional neuroendocrine tumors. Cancer 1993; 72:
244–248.
75. Plockinger U., Dienemann D., Quabbe H.J. Gastrointestinal
side''effects of octreotide during long''term treatment of
acromegaly. J. Clin. Endocrinol. Metab. 1990; 71:
1658–1662.
76. Oberg K., Norheim I., Lind E. et al. Treatment of malignant
carcinoid tumors with human leukocyte interferon: long-term
results. Cancer Treat. Rep. 1986; 70: 1297–1304.
77. Valimaki M., Jarvinen H., Salmela P. et al. Is the treatment of
metastatic carcinoid tumor with interferon not as successful
as suggested? Cancer 1991; 67: 547–549.
78. Doberauer C., Mengelkoch B., Kloke O. et al. Treatment of
metastatic carcinoid tumors and the carcinoid syndrome with
recombinant interferon. Acta Oncol. 1991; 30: 603–605.
79. Creutzfeldt W., Bartsch H.H., Jacubaschke U., Stockmann F.
Treatment of gastrointestinal endocrine tu mours with interferon'' and octreotide. Acta Oncol. 1991; 30: 529–535.
80. Moertel C.G., Rubin J., Kvols L.K. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with
recombinant leukocyte A interferon. J. Clin. Oncol. 1989; 7:
865–868.
81. Janson E.T., Ronnblom L., Ahlstrom H. et al. Treatment with interferon versus α''interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid
tumors: a randomized trial. Ann. Oncol. 1992; 3: 635–638.
82. Oberg K., Alm G., Magnusson A. et al. Treatment of malignant
carcinoid tumors with recombinant interferon alfa''2b: development of neutralizing interferon antibodies and possible loss
of antitumor activity. J. Natl. Cancer Inst. 1989; 81: 531–535.
83. Smith D.B., Scarffe J.H., Wagstaff J., Johnston R.J. Phase II
trial of rDNA alfa''2b interferon in patients with malignant carcinoid tumor. Cancer Treat. Rep. 1987; 71: 1265–1266.
84. Tiensuu Janson E.M., Ahlstrom H., Andersson T., Oberg K.E.
Octreotide and interferon alfa: a new combination for the
treatment of malignant carcinoid tumours. Eur. J. Cancer
1992; 28A:1647–1650.
85. Jacobsen M.B., Hanssen L.E., Kolmannskog F. et al.
Interferon''α 2b, with or without prior hepatic artery embolization: clinical response and survival in mid''gut carcinoid
patients. The Norwegian Carcinoid Study. Scand. J.
Gastroenterol. 1995; 30: 789–796.
86. Dirix L.Y., Vermeulen P.B., Fierens H. et al. De Schepper B,
Corthouts B., Van Oosterom A.T.: Long''term results of continuous treatment with recombinant interferon''α in patients
with metastatic carcinoid tumors – an antiangiogenic effect?
Anticancer. Drugs 1996; 7: 175–181.
87. Oberg K., Eriksson B. The role of interferons in the management of carcinoid tumors. Acta Oncol. 1991; 30: 519–522.
88. Nold R., Frank M., Kajdan U. et al. Combined treatment of
metastatic endocrine tumors of the gastrointestinal tract with
octreotide and interferon''α (in German). Z. Gastroenterol.
1994; 32: 193– 197.
89. Kolby L., Persson G., Franzen S., Ahren B. Randomized clinical trial of the effect of interferon''α on survival in patients
with disseminated midgut carcinoid tumours. Br. J. Surg.
2003; 90: 687–693.
90. Frank M., Klose K.J., Wied M. et al. Combination therapy with
octreotide and α''interferon: effect on tumor growth in
metastatic endocrine gastroenteropancreatic tumors. Am. J.
Gastroenterol. 1999; 94: 1381–1387.
91. Oberg K. Chemotherapy and biotherapy in the treatment of
neuroendocrine tumours. Ann. Oncol. 2001; 12 (suppl. 2):
S111–S114.
92. Rougier P., Mitry E. Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 2000; 62 (suppl.
1):73–78.
93. Pelley R.J., Bukowski R.M. Recent advances in systemic
therapy for gastrointestinal neuroendocrine tumors. Curr.
Opin. Oncol. 1999; 11: 32–37.
94. De Jong M., Breeman W.A., Bernard H.F. et al. Therapy of
neuroendocrine tumors with radiolabeled somatostatin analogues. Q. J. Nucl. Med. 1999; 43: 356–366.
95. De Jong M., Breeman W.A., Bakker W.H. et al. Comparison
of 111 In''labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res. 1998; 58:
437–441.
96. Stolz B., SmithJones P., Albert R. et al. Somatostatin analogues for somatostatin''receptor''mediated radiotherapy of
cancer. Digestion 1996; 57 (suppl. 1):17–21.
97. Valkema R., De Jong M., Bakker W.H. et al. Phase I study of
peptide receptor radionuclide therapy with [In''DTPA]
octreotide: the Rotterdam experience. Semin. Nucl. Med.
2002; 32: 110–122.
98. Waldherr C., Pless M., Maecke H.R. et al. The clinical value of
[90 Y''DOTA]'' D ''Phe 1 ''Tyr 3 –octreotide (90 Y''DOTATOC) in
the treatment of neuroendocrine tumours: a clinical phase II
study. Ann. Oncol. 2001; 12: 941–945.
99. Waldherr C., Pless M., Maecke H.R. et al. Tumor response
and clinical benefit in neuroendocrine tumors after 7.4 GBq
90 Y''DOTATOC. J. Nucl. Med. 2002; 43: 610–616.
100. Waldherr C., Schumacher T., Maecke H.R. et al. Does
tumor response depend on the number of treatment sessions at constant injected dose using 90 Y''DOTATOC in neuroendocrine tumors? Eur. J. Nucl. Med. 2002; 29
(suppl.):S100.
101. Virgolini I., Britton K., Buscombe J. et al. In- and YDOTA-lanreotide: results and implications of the MAURITIUS trial.
Semin. Nucl. Med. 2002; 32: 148–155.
102. Virgolini I., Traub T., Novotny C. et al. Experience with indium-111 and yttrium''90'' labeled somatostatin analogs. Curr.
Pharm. Des. 2002; 8: 1781–1807.
103. De Jong M., Bree man W.A., Bernard B.F. et al. Tumor
response after [90 Y''DOTA 0, Tyr 3]oc '' treotide radionuclide
therapy in a transplantable rat tumor model is dependent on
tumor size. J. Nucl. Med. 2001; 42: 1841–1846.
104. Chinol M., Bodei L., Cremonesi M. Receptor''mediated
radiotherapy with Y''DOTA'' D -Phe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin.
Nucl. Med. 2002; 32: 141–147.
105. Paganelli G., Zoboli S., Cremonesi M. et al. Receptor-mediated radiotherapy with 90YDOTA- D -Phe 1 -Tyr 3 -octreotide.
Eur. J. Nucl. Med. 2001; 28: 426–434.
106. Valkema R., Kvols L., Jamar F. et al. Phase I study of therapy with 90 Y''SMT487 (Octreo'' Ther) in patients with somato''
statin receptor'' positive tumors. J. Nucl. Med. 2002; 5
(suppl.):33P.
107. Bodei L., Cremonesi M., Zoboli S. et al. Receptor- mediated
radionuclide therapy with 90 Y''DOTATOC in association with
amino acid infusion: a phase I study. Eur. J. Nucl. Med. Mol.
Imaging 2003; 30: 207–216.
108. Rolleman E.J., Valkema R., de Jong M. et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a
combination of lysine and arginine. Eur. J. Nucl. Med. Mol.
Imaging. 2003; 30: 9–15.
109. Bushnell D., O’Dorisio T., Menda Y. et al. Evaluating the clinical effectiveness of 90 YSMT487 in patients with neuroendocrine tumors. J. Nucl. Med. 2003; 44: 1556–1560.
110. De Jong M., Breeman W.A., Bernard B.F. et al. [177 Lu-DOTA 0 ,Tyr 3 ]octreotate for somatostatin receptor''targeted
radionuclide therapy. Int. J. Cancer 2001; 92: 628–633.
111. Kwekkeboom D.J., Bakker W.H., Kooij P.P. et al. [177 Lu-DOTA 0, Tyr 3] octreotate: comparison with [ 111 In''DTPA 0 ]
octreotide in patients. Eur. J. Nucl. Med. 2001; 28:
1319–1325.
112. De Jong M., Bernhard H..F, Breeman W.A.P. et al.
Combina

Management of patients with differentiated neuroendocrine tumors of jejunum and ileum (according to international guidelines)

Keywords: